REFRACTORY PERIODONTAL DISEASE

难治性牙周病

• 批准号: 7607009
• 负责人: Bruce J Paster
• 金额: $ 13.5万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607009
• 关键词: Antibodies; Bacteria; Computer Retrieval of Information on Scientific Projects Database; Data; Detection; Funding; Grant; Health; Human; Institution; Knowledge; Microbe; Oral; Oral cavity; Patients; Periodontal Diseases; Periodontitis; Production; Refractory; Refractory Disease; Research; Research Personnel; Resources; Role; Sampling; Source; Syndrome; Testing; United States National Institutes of Health; base; chemokine; cytokine; microbial; microorganism; monocyte; oral bacteria; peripheral blood; receptor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Currently about 15% of periodontitis patients fail conventional therapy and are deemed "refractory". This study examines the hypothesis that refractory periodontal disease is distinct from non-refractory periodontal disease and seeks means for prospectively identifying these patients. We will test the hypothesis that subjects with refractory disease can be distinguished from subjects with treatable periodontitis and with periodontal health, based on microbial profiles. This will identify those bacterial species that are useful for distinguishing between refractory and treatable periodontitis and identifying health. Second, we will test the hypothesis that subjects with refractory disease can be distinguished from those with treatable periodontitis, and with periodontal health, based upon antibody levels to periodontal bacteria and cytokine production by peripheral blood monocytes. This will identify key host markers. Third, we will develop a Human Oral Microbe Microarray (HOMM) for the detection of the 600 species found in the human oral cavity. The microbial samples used above will be re-analyzed using the essentially complete microbial coverage provided by this new microarray. Fourth, we will use the above combined data to differentiate refractory periodontitis from treatable periodontitis and health, and to identify refractory syndromes. Completion of this project will fill major gaps in our knowledge of the role of the total oral flora and of cytokines, chemokines, and their receptors, to better clarify the interaction between humans and their resident oral microorganisms.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 目前约15%的牙周炎患者常规治疗失败并被认为是“难治性”。 本研究检验了难治性牙周病与非难治性牙周病不同的假设，并寻求前瞻性识别这些患者的方法。 我们将检验以下假设：根据微生物谱，可以将患有难治性疾病的受试者与患有可治疗牙周炎且牙周健康的受试者区分开来。 这将识别出有助于区分难治性牙周炎和可治疗牙周炎并确定健康状况的细菌种类。 其次，我们将检验以下假设：根据牙周细菌的抗体水平和外周血单核细胞产生的细胞因子，可以将患有难治性疾病的受试者与可治疗的牙周炎受试者区分开来，并且牙周健康。 这将识别关键的宿主标记。 第三，我们将开发人类口腔微生物微阵列（HOMM），用于检测人类口腔中发现的 600 种微生物。 上面使用的微生物样品将使用这种新微阵列提供的基本完整的微生物覆盖进行重新分析。 第四，我们将利用上述综合数据来区分难治性牙周炎与可治疗牙周炎和健康，并识别难治性综合症。 该项目的完成将填补我们对口腔总菌群以及细胞因子、趋化因子及其受体的作用的认识的主要空白，从而更好地阐明人类与其常驻口腔微生物之间的相互作用。